Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
|Year of publication||2010|
|Type||Article in Periodical|
|Magazine / Source||American Journal of Hematology|
|MU Faculty or unit|
|Field||Oncology and hematology|
|Keywords||persistent splenomegaly; CML; CHR|
|Description||Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment.|